

Keisuke Kataoka

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6349970/publications.pdf>

Version: 2024-02-01

139
papers

8,239
citations

81839

39
h-index

51562

86
g-index

151
all docs

151
docs citations

151
times ranked

14426
citing authors

#	ARTICLE	IF	CITATIONS
1	Whole-genome landscape of adult T-cell leukemia/lymphoma. <i>Blood</i> , 2022, 139, 967-982.	0.6	44
2	Soluble PD-L1 works as a decoy in lung cancer immunotherapy via alternative polyadenylation. <i>JCI Insight</i> , 2022, 7, .	2.3	20
3	Heterozygous Dnmt3a R878C induces expansion of quiescent hematopoietic stem cell pool. <i>Experimental Hematology</i> , 2022, 109, 45-54.	0.2	0
4	Outcome of therapy-related myelodysplastic syndrome and oligoblastic acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: A propensity score matched analysis. <i>Hematological Oncology</i> , 2022, 40, 752-762.	0.8	5
5	Description of longitudinal tumor evolution in a case of multiply relapsed clear cell sarcoma of the kidney. <i>Cancer Reports</i> , 2022, 5, e1458.	0.6	3
6	PD-L1-expressing extranodal diffuse large B-cell lymphoma, NOS with and without <i>PD-L1</i> 3'UTR structural variations. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2022, 62, 106-113.	0.3	4
7	Feasibility and clinical utility of comprehensive genomic profiling of hematological malignancies. <i>Cancer Science</i> , 2022, 113, 2763-2777.	1.7	11
8	Multiple mutations within individual oncogenes. <i>Cancer Science</i> , 2021, 112, 483-489.	1.7	10
9	XPO1 inhibitors represent a novel therapeutic option in Adult T-cell Leukemia, triggering p53-mediated caspase-dependent apoptosis. <i>Blood Cancer Journal</i> , 2021, 11, 27.	2.8	3
10	Frequent genetic alterations in immune checkpoint-related genes in intravascular large B-cell lymphoma. <i>Blood</i> , 2021, 137, 1491-1502.	0.6	49
11	Off-the-shelf bone marrow-derived mesenchymal stem cell treatment for acute graft-versus-host disease: real-world evidence. <i>Bone Marrow Transplantation</i> , 2021, 56, 2355-2366.	1.3	23
12	Molecular classification and diagnostics of upper urinary tract urothelial carcinoma. <i>Cancer Cell</i> , 2021, 39, 793-809.e8.	7.7	65
13	Loss-of-function mutations in BCOR contribute to chemotherapy resistance in acute myeloid leukemia. <i>Experimental Hematology</i> , 2021, 101-102, 42-48.e11.	0.2	6
14	Single-Cell Analysis of the Multicellular Ecosystem in Viral Carcinogenesis by HTLV-1. <i>Blood Cancer Discovery</i> , 2021, 2, 450-467.	2.6	10
15	Expression of telomerase reverse transcriptase in peripheral T-cell lymphoma. <i>Cancer Medicine</i> , 2021, 10, 6786-6794.	1.3	4
16	The HTLV-1 viral oncoproteins Tax and HBZ reprogram the cellular mRNA splicing landscape. <i>PLoS Pathogens</i> , 2021, 17, e1009919.	2.1	19
17	Functional Roles of <i>DDX41</i> Mutations in the Development of Myeloid Malignancies. <i>Blood</i> , 2021, 138, 150-150.	0.6	0
18	Highly immunogenic cancer cells require activation of the WNT pathway for immunological escape. <i>Science Immunology</i> , 2021, 6, eabc6424.	5.6	64

#	ARTICLE	IF	CITATIONS
19	TP53 and PTEN mutations were shared in concurrent germ cell tumor and acute megakaryoblastic leukemia. <i>BMC Cancer</i> , 2020, 20, 5.	1.1	16
20	Frequent mutations that converge on the NFKBIZ pathway in ulcerative colitis. <i>Nature</i> , 2020, 577, 260-265.	13.7	168
21	VAV1 mutations contribute to development of T-cell neoplasms in mice. <i>Blood</i> , 2020, 136, 3018-3032.	0.6	15
22	Comprehensive genetic analysis of pediatric germ cell tumors identifies potential drug targets. <i>Communications Biology</i> , 2020, 3, 544.	2.0	9
23	Integrated multiomics analysis of hepatoblastoma unravels its heterogeneity and provides novel druggable targets. <i>Npj Precision Oncology</i> , 2020, 4, 20.	2.3	30
24	Clinical efficacy of haematopoietic stem cell transplantation for adult adrenoleukodystrophy. <i>Brain Communications</i> , 2020, 2, fcz048.	1.5	14
25	Clinical utility of target capture-based panel sequencing in hematological malignancies: A multicenter feasibility study. <i>Cancer Science</i> , 2020, 111, 3367-3378.	1.7	11
26	Landscape of driver mutations and their clinical impacts in pediatric B-cell precursor acute lymphoblastic leukemia. <i>Blood Advances</i> , 2020, 4, 5165-5173.	2.5	33
27	PD-1 expression on tumor or stromal cells of nodal cytotoxic T-cell lymphoma: A clinicopathological study of 50 cases. <i>Pathology International</i> , 2020, 70, 513-522.	0.6	4
28	LUBAC accelerates B-cell lymphomagenesis by conferring resistance to genotoxic stress on B cells. <i>Blood</i> , 2020, 136, 684-697.	0.6	32
29	Central nervous system ganglioneuroblastoma harboring MYO5A-NTRK3 fusion. <i>Brain Tumor Pathology</i> , 2020, 37, 105-110.	1.1	5
30	TET2 haploinsufficiency alters reprogramming into induced pluripotent stem cells. <i>Stem Cell Research</i> , 2020, 44, 101755.	0.3	5
31	Landscape and function of multiple mutations within individual oncogenes. <i>Nature</i> , 2020, 582, 95-99.	13.7	79
32	Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR-mutated non-small cell lung cancer. <i>Science Immunology</i> , 2020, 5, .	5.6	160
33	Combined Cohesin-RUNX1 Deficiency Synergistically Perturbs Chromatin Looping and Causes Myelodysplastic Syndromes. <i>Cancer Discovery</i> , 2020, 10, 836-853.	7.7	51
34	Clinical application of genomic aberrations in adult T-cell leukemia/lymphoma. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2020, 60, 66-72.	0.3	9
35	Genotype-Phenotype Relationships and Therapeutic Targets in Acute Erythroid Leukemia. <i>Blood</i> , 2020, 136, 17-18.	0.6	3
36	Integrated genetic and epigenetic analysis revealed heterogeneity of acute lymphoblastic leukemia in Down syndrome. <i>Cancer Science</i> , 2019, 110, 3358-3367.	1.7	15

#	ARTICLE	IF	CITATIONS
37	Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas. <i>Leukemia</i> , 2019, 33, 1687-1699.	3.3	98
38	Identification of enhancer of mRNA decapping 4 as a novel fusion partner of MLL in acute myeloid leukemia. <i>Blood Advances</i> , 2019, 3, 761-765.	2.5	3
39	Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling. <i>Leukemia</i> , 2019, 33, 2867-2883.	3.3	148
40	PAK Kinase Inhibition Has Therapeutic Activity in Novel Preclinical Models of Adult T-Cell Leukemia/Lymphoma. <i>Clinical Cancer Research</i> , 2019, 25, 3589-3601.	3.2	16
41	PD-1 BLOCKADE IN A FRENCH SERIES OF 13 RELAPSED / REFRACTORY NK/T-CELL LYMPHOMA PATIENTS. <i>Hematological Oncology</i> , 2019, 37, 272-273.	0.8	1
42	Molecular pathogenesis of disease progression in MLL-rearranged AML. <i>Leukemia</i> , 2019, 33, 612-624.	3.3	26
43	Age-related remodelling of oesophageal epithelia by mutated cancer drivers. <i>Nature</i> , 2019, 565, 312-317.	13.7	476
44	Decreased RORC expression and downstream signaling in HTLV-1-associated adult T-cell lymphoma/leukemia uncovers an antiproliferative IL17 link: A potential target for immunotherapy?. <i>International Journal of Cancer</i> , 2019, 144, 1664-1675.	2.3	13
45	ADAM8 Is an Antigen of Tyrosine Kinase Inhibitor-Resistant Chronic Myeloid Leukemia Cells Identified by Patient-Derived Induced Pluripotent Stem Cells. <i>Stem Cell Reports</i> , 2018, 10, 1115-1130.	2.3	29
46	Prognostic relevance of genetic alterations in diffuse lower-grade gliomas. <i>Neuro-Oncology</i> , 2018, 20, 66-77.	0.6	225
47	Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma. <i>Blood</i> , 2018, 131, 215-225.	0.6	124
48	A novel genetic and morphologic phenotype of ARID2-mediated myelodysplasia. <i>Leukemia</i> , 2018, 32, 839-843.	3.3	12
49	Integrated Molecular Characterization of the Lethal Pediatric Cancer Pancreatoblastoma. <i>Cancer Research</i> , 2018, 78, 865-876.	0.4	25
50	A Cryptic NUP214-ABL1 Fusion in B-cell Precursor Acute Lymphoblastic Leukemia. <i>Journal of Pediatric Hematology/Oncology</i> , 2018, 40, e397-e399.	0.3	5
51	Physiological Srsf2 P95H expression causes impaired hematopoietic stem cell functions and aberrant RNA splicing in mice. <i>Blood</i> , 2018, 131, 621-635.	0.6	64
52	More accurate prognostic prediction in diffuse large B-cell lymphoma: beyond cell-of-origin. <i>Annals of Oncology</i> , 2018, 29, 2284-2286.	0.6	0
53	North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies. <i>Blood</i> , 2018, 132, 1507-1518.	0.6	63
54	Using patient-derived iPSCs to develop humanized mouse models for chronic myelomonocytic leukemia and therapeutic drug identification, including liposomal clodronate. <i>Scientific Reports</i> , 2018, 8, 15855.	1.6	24

#	ARTICLE	IF	CITATIONS
55	Aberrant splicing and defective mRNA production induced by somatic spliceosome mutations in myelodysplasia. <i>Nature Communications</i> , 2018, 9, 3649.	5.8	140
56	A comprehensive characterization of <i>cis</i> -acting splicing-associated variants in human cancer. <i>Genome Research</i> , 2018, 28, 1111-1125.	2.4	56
57	De Novo Mutations Activating Germline TP53 in an Inherited Bone-Marrow-Failure Syndrome. <i>American Journal of Human Genetics</i> , 2018, 103, 440-447.	2.6	33
58	RNA fusions involving <i>CD28</i> are rare in peripheral T-cell lymphomas and concentrate mainly in those derived from follicular helper T cells. <i>Haematologica</i> , 2018, 103, e360-e363.	1.7	27
59	Analysis of Genomic Predispositions to Sporadic Myeloid Neoplasms Mediated By DDX41 in Japan. <i>Blood</i> , 2018, 132, 4371-4371.	0.6	0
60	Loss of p53 induces leukemic transformation in a murine model of Jak2 V617F-driven polycythemia vera. <i>Oncogene</i> , 2017, 36, 3300-3311.	2.6	27
61	Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation. <i>Blood</i> , 2017, 129, 2347-2358.	0.6	268
62	Blastic transformation of juvenile myelomonocytic leukemia caused by the copy number gain of oncogenic <i>KRAS</i> . <i>Pediatric Blood and Cancer</i> , 2017, 64, e26496.	0.8	5
63	Constitutional abnormalities of <i>IDH1</i> combined with secondary mutations predispose a patient with Maffucci syndrome to acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26647.	0.8	9
64	A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy. <i>Cell Reports</i> , 2017, 19, 1874-1887.	2.9	104
65	Loss of DNA Damage Response in Neuroblastoma and Utility of a PARP Inhibitor. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	43
66	Genetic alterations in adult T-cell leukemia/lymphoma. <i>Cancer Science</i> , 2017, 108, 1719-1725.	1.7	60
67	TANSLOCATIONS INVOLVING CD28 ARE RARE IN PERIPHERAL T-CELL LYMPHOMAS. <i>Hematological Oncology</i> , 2017, 35, 164-165.	0.8	1
68	Recurrent SPI1 (PU.1) fusions in high-risk pediatric T cell acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2017, 49, 1274-1281.	9.4	100
69	Identification of the genetic and clinical characteristics of neuroblastomas using genome-wide analysis. <i>Oncotarget</i> , 2017, 8, 107513-107529.	0.8	23
70	DNMT3A R882 mutants interact with polycomb proteins to block haematopoietic stem and leukaemic cell differentiation. <i>Nature Communications</i> , 2016, 7, 10924.	5.8	64
71	Aberrant PD-L1 expression through 3' UTR disruption in multiple cancers. <i>Nature</i> , 2016, 534, 402-406.	13.7	536
72	Variegated RHOA mutations in human cancers. <i>Experimental Hematology</i> , 2016, 44, 1123-1129.	0.2	30

#	ARTICLE	IF	CITATIONS
73	Cytoprotective autophagy maintains leukemia-initiating cells in murine myeloid leukemia. <i>Blood</i> , 2016, 128, 1614-1624.	0.6	64
74	Somatic PHF6 mutations in 1760 cases with various myeloid neoplasms. <i>Leukemia</i> , 2016, 30, 2270-2273.	3.3	35
75	Regeneration of CD8 ⁺ T Cells from T-cell-Derived iPSC Imparts Potent Tumor Antigen-Specific Cytotoxicity. <i>Cancer Research</i> , 2016, 76, 6839-6850.	0.4	93
76	Variegated RHOA mutations in adult T-cell leukemia/lymphoma. <i>Blood</i> , 2016, 127, 596-604.	0.6	98
77	Mutational Landscape and Antiproliferative Functions of ELF Transcription Factors in Human Cancer. <i>Cancer Research</i> , 2016, 76, 1814-1824.	0.4	31
78	Paroxysmal nocturnal hemoglobinuria induced by the occurrence of BCR-ABL in a PIGA mutant hematopoietic progenitor cell. <i>Leukemia</i> , 2016, 30, 1208-1210.	3.3	19
79	Genetic biomarkers for PD-1/PD-L1 blockade therapy. <i>Oncoscience</i> , 2016, 3, 311-312.	0.9	9
80	Novel mechanism of immune evasion involving PD-L1 in various cancers. <i>Translational Cancer Research</i> , 2016, 5, S928-S929.	0.4	3
81	Identification of Somatic Mutation Contributing to Chemotherapy Resistance in Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 600-600.	0.6	0
82	Gene Expression Profiles and Methylation Analysis in Down Syndrome Related Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, 4084-4084.	0.6	0
83	Structural Variations Involving Programmed Death Ligands in B-Cell and T-Cell Lymphomas. <i>Blood</i> , 2016, 128, 4105-4105.	0.6	0
84	Statistical investigation of the random variations in PIXE hair analysis. <i>International Journal of PIXE</i> , 2015, 25, 73-84.	0.4	2
85	BAALC potentiates oncogenic ERK pathway through interactions with MEK1 and KLF4. <i>Leukemia</i> , 2015, 29, 2248-2256.	3.3	30
86	Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia. <i>New England Journal of Medicine</i> , 2015, 373, 35-47.	13.9	508
87	Mutational landscape and clonal architecture in grade II and III gliomas. <i>Nature Genetics</i> , 2015, 47, 458-468.	9.4	729
88	Integrated molecular analysis of adult T cell leukemia/lymphoma. <i>Nature Genetics</i> , 2015, 47, 1304-1315.	9.4	659
89	Targeted gene correction of RUNX1 in induced pluripotent stem cells derived from familial platelet disorder with propensity to myeloid malignancy restores normal megakaryopoiesis. <i>Experimental Hematology</i> , 2015, 43, 849-857.	0.2	40
90	Next-Generation Sequencing Reveal Proviral Genome and Transcriptome in Adult T-Cell Leukemia/Lymphoma. <i>Blood</i> , 2015, 126, 3882-3882.	0.6	0

#	ARTICLE	IF	CITATIONS
91	Heterozygous Dnmt3a Mutation Induces Expansion of Hematopoietic Stem Cell Pool in a Murine Model. <i>Blood</i> , 2015, 126, 2355-2355.	0.6	14
92	Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia. <i>Oncogene</i> , 2014, 33, 5028-5038.	2.6	38
93	Recurrent somatic mutations underlie corticotropin-independent Cushing's syndrome. <i>Science</i> , 2014, 344, 917-920.	6.0	177
94	Selective intracellular delivery of proteasome inhibitors through pH-sensitive polymeric micelles directed to efficient antitumor therapy. <i>Journal of Controlled Release</i> , 2014, 188, 67-77.	4.8	67
95	Generation of induced pluripotent stem cells derived from primary and secondary myelofibrosis patient samples. <i>Experimental Hematology</i> , 2014, 42, 816-825.	0.2	22
96	The IL-2/CD25 axis maintains distinct subsets of chronic myeloid leukemia-initiating cells. <i>Blood</i> , 2014, 123, 2540-2549.	0.6	58
97	Positive feedback between NF- κ B and TNF- α promotes leukemia-initiating cell capacity. <i>Journal of Clinical Investigation</i> , 2014, 124, 528-542.	3.9	184
98	Enhanced Autophagy Promotes Survival of Peripheral Blast Cells from Murine Acute Myeloid Leukemia. <i>Blood</i> , 2014, 124, 2339-2339.	0.6	1
99	Chronological Analysis of Clonal Evolution in Acquired Aplastic Anemia. <i>Blood</i> , 2014, 124, 253-253.	0.6	4
100	Landscape of Genetic Alterations in Adult T-Cell Leukemia/Lymphoma. <i>Blood</i> , 2014, 124, 75-75.	0.6	1
101	Comprehensive Analysis of Aberrant RNA Splicing in Myelodysplastic Syndromes. <i>Blood</i> , 2014, 124, 826-826.	0.6	6
102	Novel Biological Effects and Distinct Patterns of RhoA Mutations in Adult T-Cell Leukemia/Lymphoma and Angioimmunoblastic T Cell Lymphoma. <i>Blood</i> , 2014, 124, 2215-2215.	0.6	0
103	Identification of long-term repopulating hematopoietic stem cells by Evi1. <i>Inflammation and Regeneration</i> , 2013, 33, 175-180.	1.5	0
104	Ecotropic viral integration site 1, stem cell self-renewal and leukemogenesis. <i>Cancer Science</i> , 2012, 103, 1371-1377.	1.7	46
105	NF- κ B/TNF- α Positive Feedback Loop with Active Proteasome Machinery Supports Myeloid Leukemia Initiating Cell Capacity. <i>Blood</i> , 2012, 120, 654-654.	0.6	0
106	Pretransplant Predictors and Posttransplant Sequels of Acute Kidney Injury after Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 394-400.	2.0	37
107	Improving Drug Potency and Efficacy by Nanocarrier-Mediated Subcellular Targeting. <i>Science Translational Medicine</i> , 2011, 3, 64ra2.	5.8	231
108	AML1/RUNX1 functions as a cytoplasmic attenuator of NF- κ B signaling in the repression of myeloid tumors. <i>Blood</i> , 2011, 118, 6626-6637.	0.6	54

#	ARTICLE	IF	CITATIONS
109	The negative impact of female donor/male recipient combination in allogeneic hematopoietic stem cell transplantation depends on disease risk. <i>Transplant International</i> , 2011, 24, 469-476.	0.8	35
110	Evi1 is essential for hematopoietic stem cell self-renewal, and its expression marks hematopoietic cells with long-term multilineage repopulating activity. <i>Journal of Experimental Medicine</i> , 2011, 208, 2403-2416.	4.2	157
111	Differential prognostic impact of pretransplant comorbidity on transplant outcomes by disease status and time from transplant: a single Japanese transplant centre study. <i>Bone Marrow Transplantation</i> , 2010, 45, 513-520.	1.3	30
112	Positron emission tomography in the diagnosis and therapeutic monitoring of post-transplant lymphoproliferative disorder after cord blood transplantation. <i>Bone Marrow Transplantation</i> , 2010, 45, 610-612.	1.3	1
113	Outcome and treatment of late-onset noninfectious pulmonary complications after allogeneic haematopoietic SCT. <i>Bone Marrow Transplantation</i> , 2010, 45, 1719-1727.	1.3	20
114	Plasma brain natriuretic peptide is associated with hepatic veno-occlusive disease and early mortality after allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2010, 45, 1631-1637.	1.3	5
115	Fulminant Myocarditis after Allogeneic Bone Marrow Transplantation: Successful Cytomegalovirus Therapy and Mechanical Circulatory Support for Bridge to Recovery. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 129-130.	2.0	1
116	Post-transplant lymphoproliferative disorder after adult-to-adult living donor liver transplant: case series and review of literature. <i>Leukemia and Lymphoma</i> , 2010, 51, 1494-1501.	0.6	17
117	Evi1 Is a Stem Cell-Specific Regulator of Self-Renewal Capacity In the Definitive Hematopoietic System. <i>Blood</i> , 2010, 116, 838-838.	0.6	0
118	Interstitial pneumonia associated with progression of myelodysplastic syndrome. <i>International Journal of Hematology</i> , 2009, 89, 718-719.	0.7	2
119	Influence of Pretransplantation Serum Ferritin on Nonrelapse Mortality after Myeloablative and Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 195-204.	2.0	113
120	Plasma Brain Natriuretic Peptide Is Associated with Hepatic Venous-occlusive Disease and Early Mortality After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2009, 114, 3348-3348.	0.6	0
121	Impact On Survival and Treatment of Late-Onset Noninfectious Pulmonary Complications After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2009, 114, 3318-3318.	0.6	0
122	Elevated serum levels of soluble interleukin-2 receptor in chronic eosinophilic leukemia/hypereosinophilic syndrome with FIP1L1-PDGFR α fusion gene. <i>International Journal of Hematology</i> , 2008, 87, 440-441.	0.7	1
123	Recurrence of primary hyperparathyroidism following spontaneous remission with intracapsular hemorrhage of a parathyroid adenoma. <i>Journal of Bone and Mineral Metabolism</i> , 2008, 26, 295-297.	1.3	15
124	Successful engraftment following HLA-mismatched cord blood transplantation for patients with anti-HLA Abs. <i>Bone Marrow Transplantation</i> , 2008, 42, 129-130.	1.3	10
125	Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-beta signaling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 3460-3465.	3.3	404
126	Activation of the phosphatidylinositol-3' kinase pathway and DNA synthesis by a mutant insulin-like growth factor I receptor lacking the NPXY motif. <i>Journal of Endocrinology</i> , 2004, 181, 139-146.	1.2	1

#	ARTICLE	IF	CITATIONS
127	Screening for genes involved in tissue invasion based on placenta formation and cancer cell lines with low and high metastatic potential. <i>Cancer Letters</i> , 2001, 163, 213-219.	3.2	6
128	Maf and Jun Nuclear Oncoproteins Share Downstream Target Genes for Inducing Cell Transformation. <i>Journal of Biological Chemistry</i> , 2001, 276, 36849-36856.	1.6	19
129	A Set of Hox Proteins Interact with the Maf Oncoprotein to Inhibit Its DNA Binding, Transactivation, and Transforming Activities. <i>Journal of Biological Chemistry</i> , 2001, 276, 819-826.	1.6	65
130	Myocardial lipid metabolism in compensated and advanced stages of heart failure: evaluation by canine pacing model with BMIPP. <i>Journal of Nuclear Medicine</i> , 2001, 42, 124-9.	2.8	23
131	A Carcinoembryonic Antigen Family cDNA from Mouse Placenta Encoding a Protein with a Rare Domain Composition. <i>Placenta</i> , 2000, 21, 610-614.	0.7	10
132	Roles of urokinase type plasminogen activator in a brain stab wound. <i>Brain Research</i> , 2000, 887, 187-190.	1.1	21
133	Preservation of the vulva in stage III squamous cell carcinoma with intra-arterial chemotherapy. <i>International Journal of Clinical Oncology</i> , 1999, 4, 307-310.	1.0	0
134	Nigral degeneration following striato-pallidal lesion in tissue type plasminogen activator deficient mice. <i>Neuroscience Letters</i> , 1999, 266, 220-222.	1.0	4
135	Mild hypothermia a revived countermeasure against ischemic neuronal damages. <i>Neuroscience Research</i> , 1998, 32, 103-117.	1.0	85
136	Bioactivation of cysteine conjugates of 1-nitropyrene oxides by cysteine conjugate beta-lyase purified from <i>Peptostreptococcus magnus</i> . <i>Applied and Environmental Microbiology</i> , 1995, 61, 3781-3787.	1.4	5
137	Changes in somatosensory circuits after subcortical infarct in rats. <i>Restorative Neurology and Neuroscience</i> , 1992, 4, 323-330.	0.4	0
138	Species differences in metabolic activation and inactivation of 1-nitropyrene in the liver. <i>Cancer Research</i> , 1991, 51, 3919-24.	0.4	11
139	Cranial Computed Tomographic and Electroencephalographic Abnormalities in Children with Post-Hemiconvulsive Hemiplegia. <i>European Neurology</i> , 1988, 28, 279-284.	0.6	21